Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 6/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349880 | 0.85 | MCL1 (1.00) | MCL1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL11817172 | 0.80 | ALDH1A1 (0.49) | MCL1KDM4EMAPTTLR8ALDH1A1 | |
| SCHEMBL25969102 | 0.79 | GAA (0.59) | MCL1GAAMAPTTLR8ALDH1A1 | |
| SCHEMBL2025062 | 0.78 | MCL1 (0.50) | MCL1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL14584326 | 0.78 | CYP1A2 (0.59) | MCL1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL14975317 | 0.78 | NQO2 (0.55) | MCL1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL5487330 | 0.77 | MCL1 (0.62) | MCL1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL17993263 | 0.77 | MCL1 (0.49) | MCL1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL17964122 | 0.77 | MCL1 (0.49) | MCL1KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL29364795 | 0.74 | SIGMAR1 (0.63) | MCL1KDM4EGAAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919921-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2024-03-05 | — | — | US | disclosed |
| US-20220289783-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2022-09-15 | — | — | US | disclosed |
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| US-11377464-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2022-07-05 | — | — | US | disclosed |
| CN-113621005-A | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-107406478-B | alpha-D-galactoside inhibitors of galectins | 格莱克特生物技术公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3828191-A2 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2021-06-02 | — | — | EP | disclosed |
| EP-3828191-A2 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Galecto Biotech AB (DK) | 2021-06-02 | — | — | EP | disclosed |
| EP-3250581-B1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-20 | — | — | EP | disclosed |
| EP-3250581-B1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2021-01-20 | — | — | EP | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2017-12-07 | — | — | US | disclosed |
| EP-3250581-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | Galecto Biotech AB (DK) | 2017-12-06 | — | — | EP | disclosed |
| CN-107406478-A | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | 格莱克特生物技术公司 | 2017-11-28 | — | — | CN | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016120403-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | GALECTO BIOTECH AB (DK) | 2016-08-04 | — | — | WO | disclosed |
| EP-0255643-B1 | METAL COMPLEX COMPOUND USEFUL AS A NEAR INFRARED ABSORBER | HODOGAYA CHEMICAL CO., LTD. (JP) | 1991-10-09 | — | — | EP | disclosed |
| US-4977249-A | FOR OPTICAL FILTERS OR SHIELDS | HODOGAYA CHEMICAL CO., LTD. (JP) | 1990-12-11 | — | — | US | disclosed |
| EP-0255643-A2 | Metal complex compound useful as a near infrared absorber | HODOGAYA CHEMICAL CO., LTD. (JP) | 1988-02-10 | — | — | EP | disclosed |
| US-3930672-A | Pressure-sensitive copying paper containing lactone compounds derived from pyridine-carboxylic acid | HODOGAYA CHEMICAL CO., LTD. (JA) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377464-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | MCL1 1264/4885KDM4E 3155/4885GAA 102/4885 |
| US-11919921-B2 | Galactoside inhibitor of galectins | LGALS3, LGALS1, LGALS2 | MCL1 1264/4885KDM4E 3155/4885GAA 102/4885 |
| US-20220289783-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | MCL1 1592/4885KDM4E 3342/4885GAA 96/4885 |
| US-20170349619-A1 | ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS | LGALS3, LGALS1, LGALS2 | MCL1 998/4885KDM4E 3105/4885GAA 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.